January 19, 2018 / 5:12 AM / in 4 months

BRIEF-Shenzhen Hepalink Pharmaceutical unit gets approval for new drug clinical trial in Australia

Jan 19 (Reuters) - Shenzhen Hepalink Pharmaceutical Co Ltd :

* Says its controlling Shenzhen-based biotech subsidiary gets approval for new drug Ib/IIa clinical trial in Australia

* The new drug is used for treatment of hyperlipemia

Source text in Chinese: goo.gl/4PZG6r

Further company coverage: (Beijing Headline News)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below